Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,372.00-2.51%ETH$2,574.91-4.55%GOLD$4,130.50-0.25%OIL$89.24+1.09%
Smart Investors Daily
SID Premium
Treace Medical Concepts, Inc. logo

NASDAQ · TMCI

Treace Medical Concepts, Inc.

Healthcare · Medical - Devices

$3.89

Down-$0.11 (-2.75%)

Updated Oct 8, 2026, 4:56 AM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
183.56M
P/E ratio
-3.7
Dividend yield
0.00%
52-week range
$1.17 – $5.20
Volume
250.35K
Avg. volume
634.64K

Price performance · TMCI

TMCI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

TMCI closed at $3.89 after 21 trading sessions, down 14.13% for the selected period.

Last close
$3.89
Period change
-14.13%
Period low
$3.89
Period high
$4.63
Daily close
View OHLC price history
TMCI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$3.98$4.12$3.82$3.89250.35K
Oct 6, 2026$4.53$4.53$3.98$4.00652.13K
Oct 5, 2026$4.40$4.54$4.24$4.48210.75K
Oct 2, 2026$4.37$4.41$4.22$4.39154.67K
Oct 1, 2026$4.42$4.44$4.26$4.33183.06K
Sep 30, 2026$4.62$4.62$4.43$4.44157.61K
Sep 29, 2026$4.48$4.63$4.41$4.62141.68K
Sep 28, 2026$4.49$4.50$4.385$4.48169.56K
Sep 25, 2026$4.55$4.645$4.44$4.50210.5K
Sep 24, 2026$4.51$4.625$4.41$4.54148.13K
Sep 23, 2026$4.56$4.6684$4.41$4.51318.07K
Sep 22, 2026$4.48$4.67$4.45$4.59395.99K
Sep 21, 2026$4.54$4.54$4.38$4.48316.75K
Sep 18, 2026$4.57$4.68$4.465$4.49344.76K
Sep 17, 2026$4.66$4.66$4.475$4.53196.67K
Sep 16, 2026$4.57$4.625$4.49$4.56165.59K
Sep 15, 2026$4.58$4.615$4.43$4.58161.52K
Sep 14, 2026$4.44$4.665$4.435$4.63230.24K
Sep 11, 2026$4.555$4.555$4.365$4.51147.54K
Sep 10, 2026$4.46$4.52$4.31$4.35223.5K
Sep 9, 2026$4.62$4.725$4.50$4.53113.56K

Latest TMCI news

The latest Smart Investors Daily articles mentioning TMCI.

Stock researchCompany · Overview

TMCI research

Overview

Company profile and research snapshot.

Company profile

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
TMCI recent ratings
DateFirmRatingTarget
Aug 10, 2026Truist SecuritiesHold—
Jul 16, 2026Truist SecuritiesHold—
Mar 2, 2026Lake StreetBuy—
Jan 7, 2026StifelHold—
Dec 18, 2025Truist SecuritiesHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced five-year ALIGN3D results on September 17, adding longer-term evidence for the Lapiplasty bunion-correction procedure. The final analysis included 137 of 173 treated patients, or approximately 79% of the original group. Reported radiographic recurrence was 0.8% when defined as a hallux valgus angle greater than 20 degrees and 5.3% using […]

Yahoo · Sep 17, 2026

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lap

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By